Memorial Sloan Kettering Cancer Center

CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab — followed by maintenance durvalumab, bevacizumab and olaparib — extended PFS compared with standard of care for women with non-BRCA-mutated advanced ovarian cancer.

CHICAGO — Zanidatamab induced durable responses among patients with previously treated HER2-amplified biliary tract cancer, according to study results presented at ASCO Annual Meeting.

Individuals living with HIV historically have been at higher risk for non-Hodgkin lymphoma.

Pembrolizumab demonstrated clinical activity among patients with diffuse malignant peritoneal mesothelioma, regardless of PD-L1 status or histology, according to data published in JAMA Network Open.

Individuals of African ancestry treated for colorectal cancer had fewer actionable genetic alterations than those of European ancestry, making them less likely to be eligible for immunotherapy, study results showed.

Delirium appeared associated with higher ICU and hospital mortality, as well as increased length of stay, among critically ill patients with cancer, according to data published in JCO Oncology Practice.

Partners of colorectal cancer survivors experienced long-term financial toxicity associated with worse health-related quality of life, according to results of a survey study published in JAMA Network Open.

Reactivation of double-stranded DNA viruses is an important cause of morbidity and mortality after hematopoietic stem cell transplantation.

A digital tool that tracks patient-reported symptoms helped identify post-discharge complications among women with gynecologic cancer who underwent debulking surgery, according to retrospective study results.

Intermittent milademetan appeared effective and mitigated dose-limiting hematologic adverse events among patients with advanced solid tumors and lymphomas, according to study results published in Journal of Clinical Oncology.